Literature DB >> 28789464

Association of mutant EGFR L858R and exon 19 concentration in circulating cell-free DNA using droplet digital PCR with response to EGFR-TKIs in NSCLC.

Yan-Juan Zhu1, Hai-Bo Zhang1, Yi-Hong Liu1, Ya-Zhen Zhu2, Jun Chen3, Yong Li1, Jian-Ping Bai1, Li-Rong Liu1, Yan-Chun Qu1, Xin Qu1, Xian Chen1, Guang-Juan Zheng2.   

Abstract

The present study aimed to determine the diagnostic concordance of plasma epidermal growth factor receptor (EGFR) mutation using droplet digital polymerase chain reaction (ddPCR) with tumor tissue samples and the predictive clinical significance of plasma EGFR mutation concentration. Plasma DNA samples from patients with non-small cell lung cancer (NSCLC) were analyzed for EGFR exon 21 codon 858 (L858R) mutation, deletion of exon 19 (ex19del) and exon 20 codon 790 (T790M) mutation using ddPCR. Firstly, the mutations in the plasma samples were compared with the matched tumor samples to determine the concordance. Secondly, image examination follow-ups were analyzed to assess the association between plasma EGFR mutation concentration and patients' response to EGFR-tyrosine kinase inhibitors (TKIs). A total of 51 patients with NSCLC were enrolled, including 48 newly diagnosed patients. Compared with tumor tissue samples, the sensitivity and specificity of ddPCR were 76.19% (16/21) and 96.55% (28/29) for mutant L858R, and 88.89% (8/9) and 100% (41/41) for ex19del, respectively. No patient exhibited the T790M mutation in the tumor tissue or plasma samples. Furthermore, 5 patients with the L858R mutation and 4 patients with ex19del in plasma and tumor tissue samples had been followed up with image examination for ≥3 months following EGFR-TKI treatment. The baseline mutant EGFR concentrations were positively correlated with a reduction in tumor burden (Spearman's r=0.7000, P=0.0358). When analyzed separately, ex19del concentrations (Spearman's r=1.0000, P<0.0001) were also positively correlated with the reduction, while mutant L858R concentrations were not (Spearman's r=0.7000, P=0.1881). In the present study, detection of plasma EGFR mutations using ddPCR exhibited sufficient concordance with tumor tissue sample results. Baseline plasma mutant EGFR and ex19del concentrations were significantly and positively correlated with response to EGFR-TKIs.

Entities:  

Keywords:  EGFR; NSCLC; blood biopsy; ddPCR

Year:  2017        PMID: 28789464      PMCID: PMC5530088          DOI: 10.3892/ol.2017.6425

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  22 in total

1.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Authors:  Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares
Journal:  Lancet Oncol       Date:  2012-01-26       Impact factor: 41.316

2.  The origin of circulating free DNA.

Authors:  Maniesh van der Vaart; Piet J Pretorius
Journal:  Clin Chem       Date:  2007-12       Impact factor: 8.327

Review 3.  Cell-free nucleic acids as biomarkers in cancer patients.

Authors:  Heidi Schwarzenbach; Dave S B Hoon; Klaus Pantel
Journal:  Nat Rev Cancer       Date:  2011-05-12       Impact factor: 60.716

4.  Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy.

Authors:  Tony Mok; Yi-Long Wu; Jin Soo Lee; Chong-Jen Yu; Virote Sriuranpong; Jennifer Sandoval-Tan; Guia Ladrera; Sumitra Thongprasert; Vichien Srimuninnimit; Meilin Liao; Yunzhong Zhu; Caicun Zhou; Fatima Fuerte; Benjamin Margono; Wei Wen; Julie Tsai; Matt Truman; Barbara Klughammer; David S Shames; Lin Wu
Journal:  Clin Cancer Res       Date:  2015-03-31       Impact factor: 12.531

5.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Authors:  Makoto Maemondo; Akira Inoue; Kunihiko Kobayashi; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Masao Harada; Hirohisa Yoshizawa; Ichiro Kinoshita; Yuka Fujita; Shoji Okinaga; Haruto Hirano; Kozo Yoshimori; Toshiyuki Harada; Takashi Ogura; Masahiro Ando; Hitoshi Miyazawa; Tomoaki Tanaka; Yasuo Saijo; Koichi Hagiwara; Satoshi Morita; Toshihiro Nukiwa
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

6.  Rociletinib in EGFR-mutated non-small-cell lung cancer.

Authors:  Lecia V Sequist; Jean-Charles Soria; Jonathan W Goldman; Heather A Wakelee; Shirish M Gadgeel; Andrea Varga; Vassiliki Papadimitrakopoulou; Benjamin J Solomon; Geoffrey R Oxnard; Rafal Dziadziuszko; Dara L Aisner; Robert C Doebele; Cathy Galasso; Edward B Garon; Rebecca S Heist; Jennifer Logan; Joel W Neal; Melody A Mendenhall; Suzanne Nichols; Zofia Piotrowska; Antoinette J Wozniak; Mitch Raponi; Chris A Karlovich; Sarah Jaw-Tsai; Jeffrey Isaacson; Darrin Despain; Shannon L Matheny; Lindsey Rolfe; Andrew R Allen; D Ross Camidge
Journal:  N Engl J Med       Date:  2015-04-30       Impact factor: 91.245

7.  Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer.

Authors:  Qing Zhou; Xu-Chao Zhang; Zhi-Hong Chen; Xiao-Lu Yin; Jin-Ji Yang; Chong-Rui Xu; Hong-Hong Yan; Hua-Jun Chen; Jian Su; Wen-Zhao Zhong; Xue-Ning Yang; She-Juan An; Bin-Chao Wang; Yi-Sheng Huang; Zhen Wang; Yi-Long Wu
Journal:  J Clin Oncol       Date:  2011-07-25       Impact factor: 44.544

8.  Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA.

Authors:  Geoffrey R Oxnard; Cloud P Paweletz; Yanan Kuang; Stacy L Mach; Allison O'Connell; Melissa M Messineo; Jason J Luke; Mohit Butaney; Paul Kirschmeier; David M Jackman; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2014-01-15       Impact factor: 12.531

9.  Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.

Authors:  Hua Bai; Li Mao; Hang Shu Wang; Jun Zhao; Lu Yang; Tong Tong An; Xin Wang; Chun Jian Duan; Na Mei Wu; Zhi Qing Guo; Yi Xu Liu; Hong Ning Liu; Ye Yu Wang; Jie Wang
Journal:  J Clin Oncol       Date:  2009-05-04       Impact factor: 44.544

10.  High-throughput droplet digital PCR system for absolute quantitation of DNA copy number.

Authors:  Benjamin J Hindson; Kevin D Ness; Donald A Masquelier; Phillip Belgrader; Nicholas J Heredia; Anthony J Makarewicz; Isaac J Bright; Michael Y Lucero; Amy L Hiddessen; Tina C Legler; Tyler K Kitano; Michael R Hodel; Jonathan F Petersen; Paul W Wyatt; Erin R Steenblock; Pallavi H Shah; Luc J Bousse; Camille B Troup; Jeffrey C Mellen; Dean K Wittmann; Nicholas G Erndt; Thomas H Cauley; Ryan T Koehler; Austin P So; Simant Dube; Klint A Rose; Luz Montesclaros; Shenglong Wang; David P Stumbo; Shawn P Hodges; Steven Romine; Fred P Milanovich; Helen E White; John F Regan; George A Karlin-Neumann; Christopher M Hindson; Serge Saxonov; Bill W Colston
Journal:  Anal Chem       Date:  2011-10-28       Impact factor: 6.986

View more
  9 in total

Review 1.  Current and Emerging Applications of Droplet Digital PCR in Oncology: An Updated Review.

Authors:  Susana Olmedillas-López; Rocío Olivera-Salazar; Mariano García-Arranz; Damián García-Olmo
Journal:  Mol Diagn Ther       Date:  2021-11-13       Impact factor: 4.074

2.  Detection of EGFR mutations in non-small cell lung cancer by droplet digital PCR.

Authors:  Drew F K Williamson; Sean R N Marris; Vanesa Rojas-Rudilla; Jacqueline L Bruce; Cloud P Paweletz; Geoffrey R Oxnard; Lynette M Sholl; Fei Dong
Journal:  PLoS One       Date:  2022-02-24       Impact factor: 3.240

3.  Comparison of the SuperARMS and Droplet Digital PCR for Detecting EGFR Mutation in ctDNA From NSCLC Patients.

Authors:  Wei-Neng Feng; Wei-Quan Gu; Ning Zhao; Ying-Ming Pan; Wei Luo; Hua Zhang; Jian-Miao Liang; Jie Yang; Yan-Ming Deng
Journal:  Transl Oncol       Date:  2018-03-08       Impact factor: 4.243

Review 4.  The Validity and Predictive Value of Blood-Based Biomarkers in Prediction of Response in the Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review.

Authors:  Frederik van Delft; Hendrik Koffijberg; Valesca Retèl; Michel van den Heuvel; Maarten IJzerman
Journal:  Cancers (Basel)       Date:  2020-04-30       Impact factor: 6.639

5.  The expression level of CSDAP1 in lung cancer and its clinical significance.

Authors:  Tongbai Xu; Dongsheng Li; Yuan He; Fuliang Zhang; Man Qiao; Yanhua Chen
Journal:  Oncol Lett       Date:  2018-07-23       Impact factor: 2.967

6.  Differences in the genomic profiles of cell-free DNA between plasma, sputum, urine, and tumor tissue in advanced NSCLC.

Authors:  Zhen Wu; Zhen Yang; Chun Sun Li; Wei Zhao; Zhi Xin Liang; Yu Dai; Qiang Zhu; Kai Ling Miao; Dong Hua Cui; Liang An Chen
Journal:  Cancer Med       Date:  2019-02-14       Impact factor: 4.452

7.  Diagnostic Accuracy of Droplet Digital PCR and Amplification Refractory Mutation System PCR for Detecting EGFR Mutation in Cell-Free DNA of Lung Cancer: A Meta-Analysis.

Authors:  Caichen Li; Qihua He; Hengrui Liang; Bo Cheng; Jianfu Li; Shan Xiong; Yi Zhao; Minzhang Guo; Zhichao Liu; Jianxing He; Wenhua Liang
Journal:  Front Oncol       Date:  2020-03-03       Impact factor: 6.244

8.  Comparative assessment of NOIR-SS and ddPCR for ctDNA detection of EGFR L858R mutations in advanced L858R-positive lung adenocarcinomas.

Authors:  Daisuke Akahori; Yusuke Inoue; Naoki Inui; Masato Karayama; Hideki Yasui; Hironao Hozumi; Yuzo Suzuki; Kazuki Furuhashi; Tomoyuki Fujisawa; Noriyuki Enomoto; Yutaro Nakamura; Takafumi Suda
Journal:  Sci Rep       Date:  2021-07-22       Impact factor: 4.379

9.  Expression and copy number gains of the RET gene in 631 early and mid stage non-small cell lung cancer cases.

Authors:  Ling Tan; Yerong Hu; Yongguang Tao; Bin Wang; Jun Xiao; Zhenjie Tang; Ting Lu; Hao Tang
Journal:  Thorac Cancer       Date:  2018-02-23       Impact factor: 3.500

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.